We are a commercial-stage medical device company developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Our proprietary platform technology, BAROSTIM, leverages the brain’s power to address the imbalance of the Autonomic Nervous System (“ANS”), which causes heart failure (“HF”) and other cardiovascular diseases. Our second-generation product, BAROSTIM NEO, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HF with reduced Ejection Fraction (“HFrEF”), or systolic HF. BAROSTIM NEO sends electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function.
We estimate that there are about 26 million people globally suffering from HF, including 6.2 million people in the U.S. and 8.6 million people in EU5. HF is characterized by the heart’s inability to effectively circulate blood throughout the body. This causes shortness of breath, extreme fatigue, exercise intolerance, swelling and fluid retention that affects the patient’s quality of life.
Note: Revenue and net loss figures are for the year ended Dec. 31, 2020.
(Note: CVRx upsized its IPO at pricing on June 29, 2021, by offering 7 million shares, up from 6.25 million in the prospectus, at $18 – above its $15-to-$17 range – to raise $126 million.)
|Address||9201 West Broadway Avenue, Suite 650 Minneapolis, MN 55445|
|View Prospectus:||CVRx, Inc.|
|Revenues||$6.05 mil (last 12 months)|
|Net Income||$-14.11 mil (last 12 months)|
|Price range||$18.00 - $18.00|
|Est. $ Volume||$126.0 mil|
|Manager / Joint Managers||J.P. Morgan/ Piper Sandler/ William Blair|
|Expected To Trade:||6/30/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|